Aggressive non-Hodgkin's lymphoma: long-term results of full dose CHOP chemotherapy, and analysis of prognostic determinant.
Prognostic factors for complete remission rate (CR), duration of remission and survival were analysed in a series of 150 patients with intermediate (diffuse large-cell) and high grade non-Hodgkin's lymphoma treated with full doses of CHOP over a 10 year period with a minimum follow-up of 5 years. The two factors which significantly predicted for CR were normal LDH level and absence of bone marrow involvement. For duration of CR, the only significant factor was disease bulk, while for duration of survival age, LDH and B-symptoms were all significant. 48 patients were alive and in CR at 7 years or more with a projected long term (10 years or >) overall survival of 55 percent.
Bezwoda
W R
WR
Department of Medicine, University of Witwatersrand, Parktown, Johannesburg, South Africa.
Dansey
R
R
D000293:Adolescent; D000328:Adult; D000367:Age Factors; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D003520:Cyclophosphamide / Q000627:therapeutic use; D004317:Doxorubicin / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007770:L-Lactate Dehydrogenase / Q000097:blood; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D011241:Prednisone / Q000627:therapeutic use; D011379:Prognosis; D016019:Survival Analysis; D013997:Time Factors; D014750:Vincristine / Q000627:therapeutic use
D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D007770:L-Lactate Dehydrogenase; D011241:Prednisone